3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myeloid, Acute
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Myelodysplastic Syndromes
19
Lymphoma, Non-Hodgkin
17
Leukemia, Lymphocytic, Chronic, B-Cell
15
Hodgkin Disease
15
Graft vs Host Disease
13
Lymphoma, Mantle-Cell
12
Leukemia
12
Multiple Myeloma
11
Lymphoma, Large B-Cell, Diffuse
11
Sarcoma
10
Lymphoma
10
Lymphoma, Follicular
9
Lymphoma, B-Cell, Marginal Zone
9
Burkitt Lymphoma
9
Myeloproliferative Disorders
8
Waldenstrom Macroglobulinemia
7
Tuberous Sclerosis
7
Neoplasms
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Hematologic Neoplasms
7
Congenital Abnormalities
7
Primary Myelofibrosis
6
Lymphoma, Large-Cell, Immunoblastic
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid, Accelerated Phase
6
Breast Neoplasms
6
Osteosarcoma
5
Interventions
Glutamine
2
sagopilone
1
nicotinamide-beta-riboside
1
allantoicase
1
Vitamin D
1
Vitamin B 6
1
Vitamin B 12
1
Taxoids
1
Tadalafil
1
Sirolimus
1
Prednisolone
1
Paclitaxel
1
Minocycline
1
Metformin
1
Losartan
1
Hydroxychloroquine
1
G(M1) Ganglioside
1
Fatty Acids, Omega-3
1
Exercise
1
Everolimus
1
Etoricoxib
1
Ethosuximide
1
Epoetin Alfa
1
Dietary Supplements
1
Dexamethasone
1
Cryotherapy
1
Bortezomib
1
BID protein, human
1
Acupuncture Therapy
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Peripheral Nervous System Diseases
×
Sirolimus
×
Clear all
NCT01490476
2017-05-23
AFINF2
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
10 enrolled